Clinical trial
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic…
NCT00103558 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00103558 |
|---|---|
| Title | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) |
| Official title | A Phase I/II Study of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Lumiliximab with FCR |
| Enrollment | 31 |
| Start date | Mar 1, 2004 |
| Primary completion | Jan 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Feb 11, 2005 |
| Last update posted | Oct 2, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: